Literature DB >> 31140648

Estrogen receptor alpha activates MAPK signaling pathway to promote the development of endometrial cancer.

Ai Liu1, Dan Zhang2, Xiufen Yang3, Ying Song1.   

Abstract

Endometrial cancer (EC) is a common malignant tumor of the female reproductive system in the world. For most of the treated patients, although the survival rate is improved, most patients still have a poor prognosis. The pathogenesis of EC has always been a strong scientific focus, but there is no clear conclusion. Therefore, in view of modularization, this study is to conduct an in-depth analysis on the effects of estrogen receptor alpha (ERα) regarding EC. The purpose is to identify the molecular course of EC. We obtained 10 co-expression modules, in which ANO2, EMP3, and other genes are significantly differentially expressed in patients with EC. Additionally, there are active regulatory effects in dysfunction modules, thus genes such as ANO2 and EMP3 would be identified as key genes, which are associated with the development of EC. Enrichment results showed that the module genes were significantly involved in RNA splicing, covalent chromatin modification, histone modification, and organelle fission, and other biological processes, as well as significantly regulated mitogen-activated protein kinases (MAPK) signaling pathway, Endocytosis, Rap1 signaling pathway, and viral carcinogenesis, and other signaling pathways. Finally, we identified noncoding RNA pivot including FENDRR, miR-520c-3p. Besides, transcription factors pivot including NFKB1, E2F1, and RELA which significantly regulate dysfunction module genes. Overall, our work deciphered a co-expression network involving differential gene regulation in ERα-associated EC. It helps reveal the core modules and potential regulatory factors of the diseases and enhances our understanding of the pathogenesis. More importantly, we revealed that ERα activates the MAPK signaling pathway to promote the development of EC. It helps to provide a new reference for later research.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  ERα; MAPK signaling pathway; co-expression module; endometrial carcinoma; regulatory factor

Year:  2019        PMID: 31140648     DOI: 10.1002/jcb.29027

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Exploring the mechanism and experimental verification of puerarin in the treatment of endometrial carcinoma based on network pharmacology and bioinformatics analysis.

Authors:  Zhiheng Lin; Xiaohui Sui; Wenjian Jiao; Ying Wang; Junde Zhao
Journal:  BMC Complement Med Ther       Date:  2022-06-07

2.  Expression of SUMO associated proteins in the mouse endometrium is regulated by ovarian hormones throughout the estrous cycle.

Authors:  Yi Liu; Xiaofang Ma; Xuhong Chen; Jinsheng Chen; Li Yuan; Lili Li; Yaowu Bai; Xiaozhi Liu
Journal:  Exp Ther Med       Date:  2020-01-03       Impact factor: 2.447

3.  Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis.

Authors:  Yue Chang; Min Hao; Ru Jia; Yihui Zhao; Yixuan Cai; Yun Liu
Journal:  Cancer Cell Int       Date:  2021-01-07       Impact factor: 5.722

4.  TTC36 inactivation induce malignant properties via Wnt-β-catenin pathway in gastric carcinoma.

Authors:  Lei Song; Xiaonong Guo; Fei Zhao; Wei Wang; Zhifang Zhao; Long Jin; Chengli Wu; Jibin Yao; Zhongren Ma
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

5.  Oral Contraceptive Steroids Promote Papillary Thyroid Cancer Metastasis by Targeting Angiogenesis and Epithelial-Mesenchymal Transition.

Authors:  Mohammad Hossein Dehghan; Mohammad Reza Ashrafi; Mehdi Hedayati; Setareh Shivaee; Sadegh Rajabi
Journal:  Int J Mol Cell Med       Date:  2022-01-10

Review 6.  p38β - MAPK11 and its role in female cancers.

Authors:  Periklis Katopodis; Rachel Kerslake; Athanasios Zikopoulos; Nefeli Beri; Vladimir Anikin
Journal:  J Ovarian Res       Date:  2021-06-26       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.